Axsome Reports Results of AXS-05 in the P-II (ASCEND) Study for the Treatment of Major Depressive Disorder
Shots:
- The P-II (ASCEND) study evaluate AXS-05 (45mg dextromethorphan/105mg bupropion) vs bupropion (105mg, BID for 6wks.) in a ratio (1:1) in 80 patients with MDD
- The trial met prespecified 1EPs i.e., mean reduction from baseline in MADRS total score (17.2 vs 12.1 points) @6wk., (47% vs 16%) improvement in depressive symptoms demonstrated the superiority over bupropion @1st wk., an improvement on CGI-I @1wk. & (59% vs 27%) @6wk. along with improvement on multiple 2EPs including remission (47% vs 16%), was safe & well-tolerated with similar rates of AEs
- Additionally, 51% had experienced ≥3 MDE & 23% had received 1L treatment in MDE. The results from the P-III trial of AXS-05 are expected in Q2’22
Ref: Globenewswire | Image: Axsome
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
